Literature DB >> 19491613

Use of cancer screening services in Greece and associated social factors: results from the nation-wide Hellas Health I survey.

Christine Dimitrakaki1, Dimitris Boulamatsis, Anargiros Mariolis, Nick Kontodimopoulos, Dimitris Niakas, Yannis Tountas.   

Abstract

This study estimated the rates of age-appropriate screening practices for breast, cervical, colon and prostate cancer within the general population in Greece and explored the influences of social factors on their use. Data were based on the cross-sectional Hellas Health I survey (2006) conducted on a representative sample of 1005 adults, aged 18-69 years. The percentage of women aged 21-69 years having received the papanicolaou smear test within the past 3 years was 59.4%, and the percentage of women aged 50-69 years having received mammography and the faecal occult blood test (FOBT) within the past 3 years was 53.8 and 8.3%, respectively. There were significant effects of age, education and marital status on carrying out the papanicolaou smear test, age on carrying out mammography, and existence of a family doctor on carrying out the FOBT. In men aged 50-69 years, 40.6% had received the prostate-specific antigen test and 10.9% of men had received the FOBT during the past 3 years. The percentage of men aged 50-69 years who had undergone digital rectal examination within the past 5 years was 20.3%. Multivariate analyses showed significant effects of age, social class, smoking status and type of insurance on carrying out the prostate-specific antigen test and of age on carrying out the digital rectal examination. No effects were revealed for the FOBT in men. The percentage of the population in Greece receiving screening services recommended by the European Council is low and seriously affected by social factors. Public health policies should direct their efforts towards introducing good-quality universal cancer screening and find culturally sensitive ways of addressing the barriers that prevent Greek people from adopting poor-quality cancer screening practices.

Entities:  

Mesh:

Year:  2009        PMID: 19491613     DOI: 10.1097/CEJ.0b013e32832405d6

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  6 in total

1.  Health beliefs and illness perceptions as related to mammography uptake in randomly selected women in Greece.

Authors:  Fotios Anagnostopoulos; Christine Dimitrakaki; Deborah Fitzsimmons; Gregory Potamianos; Dimitris Niakas; Yannis Tountas
Journal:  J Clin Psychol Med Settings       Date:  2012-06

2.  Participation rates in cervical cancer screening: experience in rural Northern Greece.

Authors:  A Vakfari; M Gavana; S Giannakopoulos; E Smyrnakis; A Benos
Journal:  Hippokratia       Date:  2011-10       Impact factor: 0.471

3.  Factors associated with a lack of pap smear utilization in women exposed in utero to diethylstilbestrol.

Authors:  Elizabeth A Camp; Angela W Prehn; Ji Shen; Arthur L Herbst; William C Strohsnitter; Christopher D Hobday; Stanley J Robboy; Ervin Adam
Journal:  J Womens Health (Larchmt)       Date:  2015-03-13       Impact factor: 2.681

4.  [Prevalence in the performance of mammographies in Spain: Analysis by Communities 2006-2014 and influencing factors].

Authors:  Juan Manuel Carmona-Torres; Ana Isabel Cobo-Cuenca; Noelia María Martín-Espinosa; Rosa María Piriz-Campos; José Alberto Laredo-Aguilera; María Aurora Rodríguez-Borrego
Journal:  Aten Primaria       Date:  2017-07-19       Impact factor: 1.137

5.  Predictors of adherence to screening guidelines for chronic diseases of lifestyle, cancers, and HIV in a health-insured population in South Africa.

Authors:  Leegale Adonis; Debashis Basu; John Luiz
Journal:  Glob Health Action       Date:  2014-03-14       Impact factor: 2.640

6.  Assessment of the operation of a pilot program of preventive medicine for adults in three primary care centers of Athens and Piraeus: a cross-sectional study.

Authors:  Theofano Moumtzi; Alexandros Athanasopoulos
Journal:  J Prev Med Hyg       Date:  2021-01-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.